NEW YORK, December 31, 2025, 11:51 ET — Regular session
- Regencell Bioscience Holdings (RGC) fell about 5% in late morning trade, after another two-day stretch of sharp swings.
- With no fresh company news, traders focused on thin year-end liquidity and the stock’s wide trading ranges.
Regencell Bioscience Holdings Limited shares were down 4.8% at $21.79 as of 11:51 a.m. ET, after trading between $21.44 and $23.11 in a choppy session.
The move came without any new company announcements. Regencell’s investor-relations site lists its most recent press release dated Oct. 31, and the latest SEC filing on EDGAR is its annual report filed the same day.
The pullback also tracked a softer tape across Wall Street on the final trading day of 2025, with trading volumes muted heading into the New Year’s holiday. “Describing 2025 as ‘resilient’ might be an understatement,” said Adam Turnquist, chief technical strategist at LPL Financial. Reuters
Regencell has been prone to fast moves. The stock ended Tuesday at $22.90 after ranging from $22.17 to $25.30, with 394,200 shares traded, according to historical data.
On Monday, shares opened sharply lower before reversing, MarketBeat reported, underscoring how quickly price action can flip in the name.
Regencell is a bioscience company focused on research and development of traditional Chinese medicine (TCM) candidates aimed at neurocognitive disorders including ADHD and autism spectrum disorder, according to its company profile.
The company has also faced heightened investor scrutiny after disclosing a U.S. Department of Justice subpoena. In its annual report, Regencell said it received correspondence and a subpoena from the DOJ indicating it was investigating trading in the company’s ordinary shares.
With no new disclosures since that filing, traders have leaned heavily on price action. By late morning, just over 60,000 shares had changed hands, a pace below Tuesday’s turnover.
That can matter in a stock that has shown wide intraday bands. Thin volumes can exaggerate swings when orders hit the market in clusters.
Technicians often watch “support” and “resistance” levels — areas where buying or selling has tended to show up in the past. For Regencell, traders are eyeing the $21.44 low as a near-term floor and $23.11 as the first hurdle, with last session’s $25.30 high sitting above that.
What investors are watching next is straightforward: any new SEC filing, any company comment tied to the DOJ matter, and whether volume returns after the New Year’s break.
Related articles: NASDAQ:RGC
